I

n a damning report, a major shareholder advisory firm is recommending that Mylan stockholders vote to remove 10 incumbent board members — including non-executive chairman Robert Coury and chief executive officer Heather Bresch — over the EpiPen pricing scandal and subsequent investigations. The company holds its annual meeting on June 22.

In explaining its recommendations, Institutional Shareholder Services argued the Mylan board is responsible for “significant destruction” in shareholder value and “material failures” over a number of years to respond to “warning signs,” but failed to take action to mitigate or head off the risks. As a result, the company also suffered “long-term reputational damage.”

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy